Open an account

Ensysce Biosciences

ENSC · NASDAQ

$0.4986−$0.0043 (−0.86%)TodayMarket closed ·
Prev close $0.5029

About ENSC

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 8 full-time employees. The company went IPO on 2017-12-01. The firm develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Employees
8
Headquarters
La Jolla, California
Listed
Dec 1, 2017
Sector
Health Care
Industry
Biotechnology
Website
ensysce.com

ENSC key statistics

Market cap
9.70M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
586.48K
Volume
304.22K
Open price
$0.547
High today
$0.547
Low today
$0.4986
52 Week high
$2.66
52 Week low
$0.23

Ensysce Biosciences (ENSC) at a glance

Ensysce Biosciences (ENSC) last traded at $0.4986, with a market cap of 9.70M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.4986 and $0.547. The current price is 0.0% above the day's low and 8.8% below its high.

Volume so far is 304.22K shares, below the average of 586.48K shares a day.

Over the past year Ensysce Biosciences has ranged from $0.23 to $2.66, and now sits 11% of the way up that range.

Ensysce Biosciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.20 per share against an estimate of -$0.51.

The average analyst price target is $8.41, 1587.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $8.41
Low
$8.33
Now
$0.4986
High
$8.66

ENSC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 57.5% on average.

  1. Q3 FY24: reported $1.05 per share against an estimate of -$4.51
  2. Q4 FY24: reported -$2.90 per share against an estimate of -$2.79
  3. Q1 FY25: reported -$1.39 per share against an estimate of -$3.08
  4. Q2 FY25: reported -$0.79 per share against an estimate of -$1.20
  5. Q3 FY25: reported -$1.29 per share against an estimate of -$0.8823
  6. Q4 FY25: reported -$0.75 per share against an estimate of -$1.29
  7. Q1 FY26: reported -$0.52 per share against an estimate of -$0.7446
  8. Q2 FY26: reported -$0.20 per share against an estimate of -$0.51

ENSC news

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    Why Investors Are Watching These Healthcare Movers

  • Avi Kapoor

    Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

Similar companies

Companies in the same industry as Ensysce Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.